Dimethyltryptamin/harmine - Reconnect Labs
Alternative Names: RE-01Latest Information Update: 15 Oct 2025
At a glance
- Originator Reconnect Labs
- Class Antidepressants; Antipsychotics; Carbolines; Dimethylamines; Ethanolamines; Indoles; Mood stabilisers; Neuropsychotherapeutics; Pyridones; Small molecules; Tryptamines
- Mechanism of Action Dopamine modulators; Monoamine oxidase inhibitors; Serotonin 5-HT2 receptor agonists; Serotonin receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Cocaine-related disorders
- Discontinued Mood disorders
Most Recent Events
- 15 Oct 2025 Discontinued - Phase-I for Mood disorders (In volunteers) in Switzerland (unspecified route)
- 15 Oct 2025 Phase-I clinical trials in Cocaine-related disorders (In volunteers) (unspecified route), prior to October 2025 (Reconnect Labs pipeline, October 2025)
- 15 Oct 2025 Reconnect labs plans a phase IIa trial for Cocaine-related disorders (Reconnect Labs pipeline, October 2025)